Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II, Double-blind, Randomized, Placebo-controlled, Multicentre Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of TAK-242 and (G-CSF) in Subjects with (sAH) and (ACLF)

Next Previous
Trial Profile

Phase II, Double-blind, Randomized, Placebo-controlled, Multicentre Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of TAK-242 and (G-CSF) in Subjects with (sAH) and (ACLF)

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 06 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Filgrastim (Primary) ; Resatorvid (Primary)
  • Indications Alcoholic hepatitis; Liver failure
  • Focus Adverse reactions
  • Acronyms A-TANGO Phase II Study
  • Sponsors Yaqrit

Most Recent Events

  • 28 Apr 2025 According to a Yaqrit media release, data from this study will be presented at the forthcoming European Association for the Study of the Liver (EASL) Congress, Amsterdam, May 7-10th.
  • 09 Dec 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top